RXi Pharmaceuticals Corp Share Price Nasdaq
Equities
US74979C8082
Biotechnology & Medical Research
Sales 2024 * | - | Sales 2025 * | 75M 5.9B | Capitalization | 3.42M 269M |
---|---|---|---|---|---|
Net income 2024 * | -9M -707M | Net income 2025 * | 47M 3.69B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.05 x |
P/E ratio 2024 * |
-0.41
x | P/E ratio 2025 * |
0.2
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.5% |
Managers | Title | Age | Since |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 18/06/12 |
Caitlin Kontulis
DFI | Director of Finance/CFO | - | - |
James Cardia
CTO | Chief Tech/Sci/R&D Officer | - | 14/09/17 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 18/06/12 |
Director/Board Member | 73 | 01/05/22 | |
Curtis Lockshin
BRD | Director/Board Member | 64 | 17/04/13 |
1st Jan change | Capi. | |
---|---|---|
+51.85% | 57.87B | |
+41.42% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |